Citations

Clear

5 citation(s) found for "King, Amanda".

Physical activity and molecular subtypes of colorectal cancer: a pooled observational analysis and Mendelian randomization study
Chalitsios, Christos V. , Markozannes, Georgios , Aglago, Elom K. , Berndt, Sonja I., Buchanan, Daniel D. , Campbell, Peter T. , Chan, Andrew T. , Dimou, Niki , Drew, David A. , French, Amy J. , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B., Harrison, Tabitha A. , Hullar, Meredith A.J. , Huyghe, Jeroen R. , Newton, Christina C. , Schmit, Stephanie L. , Steinfelder, Robert S. , Ugai, Tomotaka, Zaidi, Syed Hassan Ejaz , Woods, Michael O. , Andreson, Laura, Peters, Ulrike , Phipps, Amanda I , Tsilidis, Konstantinos K, Berndt, Sonja I , Cao, Yin , Chan, Andrew T , Dimou, Niki , Drew, David A , Georgeson, Peter , Giannakis, Marios , Gruber, Stephen B , Harrison, Tabitha A , Hoffmeister, Michael , Hsu, Li , Huang, Wen-Yi , Hullar, Meredith A , Huyghe, Jeroen R , Lynch, Brigid M , Moreno, Victor , Newton, Christina C , Nowak, Jonathan A , Obón-Santacana, Mireia , Ogino, Shuji , Schmit, Stephanie L , Steinfelder, Robert S , Sun, Wei , Thomas, Claire E , Toland, Amanda Ewart , Trinh, Quang M , Ugai, Tomotaka , Um, Caroline Y , Van Guelpen, Bethany , Schoen, Robert E , Woods, Michael O , Brenner, Hermann , Anderson, Laura , Pellatt, Andrew J , Phipps, Amanda I , Tsilidis, Konstantinos K , Buchanan, Daniel D , Campbell, Peter T , Aglago, Elom K , Markozannes, Georgios , Berndt, Sonja I. , Gunter, Marc J. , Hoffmeister, Michael , Huang, Wen‐Yi , Moreno, Vı́ctor , Murphy, Neil , Nowak, Jonathan A. , Obón‐Santacana, Mireia , Qu, Conghui , Sun, Wei , Thomas, Claire E. , Trinh, Quang M. , Um, Caroline Y. , Guelpen, Bethany Van , Schoen, Robert E. , Brenner, Hermann , Pellatt, Andrew J. , Tsilidis, Konstantinos K.

Mayo Clinic

JNCI Cancer Spectrum | September 29, 2025 | Volume: 9 | Issue: 6 | Pages: No page available

10.1093/jncics/pkaf095 | PMID 41031512 Get It

Abstract Background Physical activity is associated with lower colorectal cancer (CRC) risk, but its association with molecular subtypes defined by genetic and epigenetic alterations of the disease is unclear. Such information may enhance the understanding of the mechanisms related to the benefits of physical activity. Methods Pooled observational (cases: n = 5386; controls: n = 6798; studies n = 5) and genome-wide association data (cases: n = 8178; controls: n = 10 472; studies n = 5) were used. We used multivariable logistic regression models and Mendelian randomization to assess the association between physical activity and the risk of CRC subtypes defined by individual tumor markers (and marker combinations), namely microsatellite instability status, CpG island methylator phenotype status, and BRAF and KRAS mutations. We used case-only analysis to test for differences between molecular subtypes. We applied Bonferroni correction to account for multiple tests. Results In the pooled observational analysis, higher levels of physical activity were associated with lower CRC risk (Obs-per 1SD, odds ratio [OR] = 0.94, 95% confidence interval [CI] = 0.90 to 0.97), with an association that was stronger in males (Obs-per 1SD, OR = 0.91, 95% CI = 0.87 to 0.96) than in females (Obs-per 1SD, OR = 0.97, 95% CI = 0.91 to 1.03; Pinteraction = .04). Higher physical activity was associated with a lower risk of CRC across all molecular subtypes, especially in males. There was no difference in the associations by subtypes by pooled observational or Mendelian randomization analyses. The findings did not differ by study design, anatomical site, and early or late age onset of CRC. Conclusions Our findings suggest that physical activity is not differentially associated with the 4 major molecular subtypes involved in colorectal carcinogenesis, indicating that its benefits extend broadly across colorectal cancer pathogenesis.
Radiotherapy for Growing Vestibular Schwannomas
Sethi, Mantegh , Gowrishankar, Shravan , Mannion, Richard , Guilfoyle, Mathew R., Buttimore, Juliette , Gamazo, Nicola, Duke, Simon, Jena, Raj, Burton, Katherine , Fornezza, Umberto, Perini, Zeno, Mari, Cristina , Gazzola, Luca, Schouten, Sammy M , Kunst, Henricus P. M. , Bassi, Rohan, MacKeith, Samuel , Whitfield, Gillian , McBain, Catherine , Hotchkies, A , Lloyd, Simon , Obholzer, Rupert , Cheang, Ya Fang Amanda, Thomas, Nick, Barazi, Sinan, Maratos, Eleni, Hassan, Sheila, Tancu, Cornel, Kitchen, Neil , Marinelli, John P. , Carlson, Matthew L., Link, Michael J. , Tysome, James Russell , Donnelly, Neil P. , Axon, Patrick , Bance, Manohar , Jena, Raj, Burton, Katherine, Jefferies, Sarah , Mari, Cristina, Gazzola, Luca , Compter, Inge , Eekers, Daniëlle B. P. , Jeyaretna, Deva Sanjeeva , Colaco, Rovel J. , Shapey, Jonathan , Carlson, Matthew L. , Borsetto, Daniele

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 4, 2025 | Volume: 151 | Issue: 10 | Pages: 931

10.1001/jamaoto.2025.1953 | PMID 40906473 Get It

Importance In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed. Objective To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy. Design, Setting, and Participants This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025. Exposures Radiotherapy as an initial treatment for VS. Main Outcomes and Measures The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery. Results A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure. Conclusions and Relevance The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.
Prevalence of symptomatic toxicities for novel therapies in adult oncology trials: a scoping review
King, Amanda , Vasilj, Tamara , Cooper, Diane, Vera, Elizabeth , Berhanu, Sefanit, Johnson, Morgan , Locke, Ciara, McIver, Bennett , Basch, Ethan, Cappeleri, Joseph, Dueck, Amylou, Jones, Lee , Minasian, Lori M. , Mendoza, Tito R. , Dueck, Amylou C. , Cappelleri, Joseph C. , Dueck, A. C. , King, Amanda L , Basch, Ethan , Cappelleri, Joseph C , Gilbert, Mark R , Jones, Lee , Li, Yuelin , Reeve, Bryce B. , Armstrong, Terri S , Mendoza, Tito , Johnson, Morgan , Li, Yuelin , Armstrong, Terri S.

Mayo Clinic

JNCI Cancer Spectrum | March 31, 2025 | Volume: 9 | Issue: 3 | Pages: No page available

10.1093/jncics/pkaf036 | PMID 40152251 Get It

Abstract Background Patients’ self-report of their symptoms can provide important data for the evaluation of treatment benefit and tolerability of oncology drugs. Contemporary treatment approaches, including immunotherapy and molecular targeted therapies, have unique toxicities based on their novel mechanisms of action. This scoping review aimed to summarize evidence from existing reviews and clinical practice guidelines to examine the type and prevalence of toxicities including symptomatic adverse events (sympAEs) for adult cancer patients to inform clinical care and therapeutic trials. Methods A systematic search of PubMed, Web of Science, and Embase was performed using predefined eligibility criteria. Thirty-one literature reviews and 3 clinical practice guidelines met inclusion criteria and were selected for review and data abstraction. Results Findings from this scoping review demonstrated several leading sympAEs that were reported across immunotherapy and targeted therapy drugs, including fatigue, diarrhea, and rash. In addition to these more prevalent sympAEs, there were some less frequently reported class-specific sympAEs, which had potential for significant harm or disability to the patient if not properly identified and treated. Many studies reported toxicities as AEs or syndromes solely using data reported by clinicians without additional self-report from patients. Conclusion We identified several core sympAEs experienced by patients participating in oncology trials using immunotherapy and targeted therapy agents, which has implications for future trial design and drug labeling. Future cancer trials should assess patient-reported sympAEs based on the identified drug mechanism to inform the tolerability of these newer agents and enhance patient safety during trial participation and clinical care.
Optimizing Post-Cesarean Opioid Prescription Practices at Mayo Clinic: A Quality Improvement Initiative
Kim, Sharon, King, Amanda N., Parikh, Pavan , Sangtani, Ajleeta , Brodrick, Ellen M., King, Amanda , Shazly, Sherif, Brodrick, Ellen, Thompson, Angela , Shazly, Sherif A. , Thompson, Angela Knight

Mayo Clinic

American Journal of Perinatology | November 28, 2021 | Volume: 39 | Issue: 04 | Pages: 337-341

10.1055/s-0041-1739491 | PMID 34839479 Get It

Objective Optimal prescriptions practices of opioids in the post-cesarean period remain controversial. The primary aim of this initiative was to minimize unused prescription narcotic medication, with a goal of ≤4 leftover pills of 5-mg oxycodone at postoperative day (POD) 14 without affecting pain or satisfaction measures. Study Design This was a prospective longitudinal quality improvement (QI) initiative starting in 2017 utilizing the DMAIC methodology. The measurement phase consisted of validated surveys over 3 months, along with chart review to determine current institutional prescription practices and predictors of outpatient opioid use. Resulting recommendations were adopted, and 1 year later, all patients undergoing cesarean were surveyed for 3 months to determine the effectiveness of the intervention. The study was approved by the Department's QI Committee. Results The response rate was 48%, with 50 of 101 patients completing surveys pre-intervention and 52 of 111 post-intervention. Pre-intervention, surplus medication was predicted (p <0.05) only by the quantity of the opioid prescription. In addition, patients who required ≤37.5 morphine milligram equivalents (MMEs) during the inpatient postoperative stay did not require outpatient narcotic prescriptions. Thereafter, a strategy of matching inpatient use to outpatient prescription 1:1 in a linear regression model (p <0.001, R 2 0.55) optimally matched patient needs up to 200 MME. In the post-intervention survey, mean (SD) prescription decreased from 17.6 (13.7) MME to 8.4 (8.3) MME (p <0.01); 39% compared with 16% of women were discharged without a prescription (p <0.01); and amongst all patients 82.7% compared with 59.6% (p <0.01) had ≤4 pills remaining without differences in patient satisfaction or pain perception. Conclusion This initiative highlights a practical approach to QI utilizing industry techniques in health care. This approach resulted in significant reductions in over-prescription and unused medication, without impacting pain or satisfaction scores. Key Points
Hypertensive disorders of pregnancy and menopausal symptoms: a cross-sectional study from the data registry on experiences of aging, menopause, and sexuality
King, Amanda N., Kattah, Andrea G. , Kuhle, Carol L. , Sood, Richa , Kling, Juliana M. , Mara, Kristin C. , Kapoor, Ekta , King, Amanda , Mara, Kristin C , Kling, Juliana M , Faubion, Stephanie S.

Mayo Clinic

Menopause | August 18, 2020 | Volume: 28 | Issue: 1 | Pages: 25-31

10.1097/gme.0000000000001638 | PMID 32810078 Get It

Abstract Objective: Hypertensive disorders of pregnancy and menopausal symptoms, specifically vasomotor symptoms, have both been associated with cardiovascular disease risk in women. However, data are sparse on the association between these two female-specific cardiovascular risk factors. This study was conducted to investigate the association between a history of a hypertensive disorder of pregnancy and menopausal symptoms. Methods: This was a cross-sectional study of women aged 40 to 65 years seen for specialty consultation in women's health clinics at Mayo Clinic Rochester, MN and Scottsdale, AZ, between May, 2015 and September, 2019. A self-reported history of hypertensive disorders of pregnancy served as the independent variable, and menopause symptoms as assessed by the Menopause Rating Scale were the primary outcome measure. Results: Of 2,684 women included in the analysis, 180 had a self-reported history of a hypertensive disorder of pregnancy. The total menopausal symptom scores as well as somatic and psychological domain scores were higher in women with a history of a hypertensive disorder of pregnancy compared to women without a history of a hypertensive disorder of pregnancy or to women without a pregnancy. On multivariable analysis, women with a hypertensive disorder of pregnancy using hormone therapy had significantly higher total menopause symptom scores than women with no such history. Conclusions: In this large cross-sectional study, a history of hypertensive disorders of pregnancy was associated with more bothersome menopausal symptoms. Additional study is needed to determine the strength of this association, underlying mechanisms of the association, and clinical implications for cardiovascular risk prediction in women.